Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome Marco Meglio

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Todays Updates

Real-World Use of Clinical Biomarkers in the Updated Multiple Sclerosis Diagnostic Criteria Isabella Ciccone, MPH, Agne Straukiene, MD, Daniel Ontaneda, MD, PhD, Carrie Hersh, DO, MSc, FAAN

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

From the Field: Neurologist-Written Insights From 2025 NeurologyLive® Staff

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Todays Updates

Real-World Use of Clinical Biomarkers in the Updated Multiple Sclerosis Diagnostic Criteria Isabella Ciccone, MPH, Agne Straukiene, MD, Daniel Ontaneda, MD, PhD, Carrie Hersh, DO, MSc, FAAN

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

From the Field: Neurologist-Written Insights From 2025 NeurologyLive® Staff

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care

Latest News

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

News All Time

What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers Marco Meglio

Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.

Genetic Testing in Adult Epilepsy: GEAN’s Plan to Standardize Practice and Study Adult Outcomes Marco Meglio

Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

2024 Primary Stroke Prevention Guidelines: Key Takeaways and Clinical Implications Walter Kernan, MD, Isabella Ciccone, MPH

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs Marco Meglio

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

NeurologyLive® Friday 5 — December 12, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine Isabella Ciccone, MPH

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

Recommended News For You

Dissociative identity disorder: method or fact?

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

Including Bereavement in the Care Continuum.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

High levels of traumatic stress found in caregivers of adult cancer patients

Study recommends new grading system for invasive squamous cell carcinoma of the lung

Prostate cancer early detection system eliminates need for biopsy.

Recommended Articles For You

Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology 

Unlocking the Secrets of Leukemic Stem Cells: A Path to Better Blood Cancer Treatments 

Understanding Villous Adenoma: Causes, Symptoms, and Treatments 

Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC

2.

PFS in R/R Mantle Cell Lymphoma is Improved by Ibrutinib-Venetoclax.

3.

Products for Intimate Care and Cancer; Boost for Colorectal Cancer Stool Tests; Ultrasonic Biopsy?

4.

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

5.

Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'

1.

How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology

2.

Uncovering the Subtle Signs of Prostate Cancer: Early Detection is Key

3.

Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment

4.

Understanding Macrocytosis: Causes, Symptoms, and Treatment Options 

5.

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot